# Probably Genetic

> Patient-identification and rare-disease data platform connecting testing pathways with institutional research needs.

## Why it is interesting

The investment case depends on research-ready data quality, patient-access economics and repeat institutional use rather than profile counts alone.

## Profile

- **Latest funding:** Series A — $12M (October 14, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $12M
- **Stage:** series-a
- **Status:** private
- **Industries:** ai-ml, healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-10-20
- **Latest funding investors:** Threshold Ventures, Y Combinator, Other unnamed existing investors

## Funding history

- Series A · $12M · October 14, 2026
  Source: https://www.fiercehealthcare.com/health-tech/probably-genetic-raises-12m-scale-rare-disease-dataset-support-drug-discovery

## Investors in our directory

- https://venturecapitaltracker.com/fund/threshold-ventures
- https://venturecapitaltracker.com/fund/y-combinator

## Related articles

- https://venturecapitaltracker.com/probably-genetic-12m-series-a-rare-disease-data

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 20, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/probably-genetic